MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerThomas Powles, Nicholas J. Vogelzang, Joseph P. Eder et al.|Nature|2014Cited by 2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun Vasant Balar, Dean F. Bajorin, Matthew D. Galsky et al.|The Lancet|2016Cited by 2.2k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial CarcinomaThomas Powles, Petros Grivas, Se Hoon Park et al.|New England Journal of Medicine|2020Cited by 1.5k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Alain Ravaud, Edward E. Kadel et al.|The Lancet|2017Cited by 1.4k
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trialThomas Powles, Felipe Reyes, Tibor Csőszi et al.|The Lancet Oncology|2021Cited by 645